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The aim of this study is to report complications of transcatheter ASD clo-
sure using the Amplatzer Septal Occluder (ASO) (St Jude Medical). 
From December 1999 to October 2013 (April 2014), 760 patients under-
went ASD closure with the ASO. Closure was mostly performed under gen-
eral anaesthesia and transoesophageal echocardiography control. Choice of the
device diameter was established after balloon sizing and measurement of the
stretched diameter. 
Mean age of the patients was 31.9±22 years (0.5 month – 84 years). The
stretched diameter was 22.5±6.6 mm (5-40mm) and device dimension
22±6.7mm (4-40mm). Duration of the procedure was 41±15 minutes (10-120
minutes) and fluoroscopic time 7.63±6.65 minutes (1-92 minutes). Dose of
radiation was 18.7±22 Gy.cm2 (median 12 Gy.cm2). 
Implantation succeeded in 96.3% of pts and failure was mainly related to
deficient rim. No device related death was noticed. Embolization occurred in
4 pts (0.5%): 1 in the aorta, 1 in the left ventricle, and 2 in the pulmonary
artery. All but one underwent surgical extraction and ASD closure. The
patient with aortic embolization had percutaneous device extraction and
underwent subsequently successful implantation with a larger device. No
patient required blood transfusion for any groin hematoma. One patient
without aortic rim had hemopericardium one month after implantation; this
was corrected by drainage with no recurrence and ASD full occlusion was
noticed on colour Doppler control. No late complication was observed. The
rate of full occlusion on Doppler control is more than 90%, and the remain-
ings have trivial shunt.
Transcatheter ASD occlusion with the Amplatzer Septal Occluder is a safe
and effective procedure. The rate of immediate complication is very low and
need for immediate surgery following the implantation is rare (<1%). No
device related late complications were reported up to 15 years after implanta-
tion. The risk of aortic perforation in absence of anterior rim (observed in
about 20% of pts) is trivial and not a real limitation in clinical practice.
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Objective: To describe the early and midterm outcome after atrio-ventri-
cular valve (AVV) procedure in patients with univentricular hearts (UVH) and
to identify risk factors for AVV reoperation and death. 
Methods: Retrospective review of patients undergoing procedure for AVV
regurgitation at any phase of univentricular palliation from 1998-2013. Patient
and procedure related variables were analyzed.
Results: 28 consecutive patients underwent 34 procedures for moderate+
AVV regurgitation at a median age of 3.7 years. 29% of patients had a
common, 25% had dominant left, 14% had dominant right AVV and 32% two
AVV. All patients benefited from valve repair at first procedure without early
mortality. At hospital discharge patients preserved their ventricular function
(FS <30%: preop 17% vs. postop 21%, NS) and only 14% had moderate+
residual regurgitation. Dominant left AVV and postoperative moderate+
regurgitation were univariate risk factors for death and transplantation.
Younger age, need for repair before superior cavo-pulmonary shunt and
significant residual regurgitation were univariate risk factors for AVV reopera-
tion. Freedom from death and transplantation was 84% (CI 95%±0.14) at 5
and 10 years. Survival free from AVV reoperation was 77% (CI 95%±0.18)
at 5 years and 66% at 10 years (CI 95±0.25). At last visit, 91% of survivors
were in class NYHA 1-2 without ventricular dysfunction and with mild or less
AVV regurgitation.
Conclusion: Patients with UVH and moderate+ atrio-ventricular valve
regurgitation can profit from AVV repair without deterioration of their ven-
tricular function but remain at increased risk for death and AVV reoperation.
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Aim: to assess the impact of different scanning protocols on radiation dose
and image quality for pediatric coronary computed tomography.
Materials and Methods: 100 children underwent coronary computed
tomography after arterial switch operation from November 2012 to March
2014. Scans were done using two different scanner models without difference
in scanning and image reconstruction parameters: Lightspeed VCT and Dis-
covery HD750, 64-slice from GE Healthcare. Two consecutive changes in
scanning protocols were performed: 1) the use of adaptive statistical iterative
reconstruction (ASIR) instead of filtered back projection (FBP) for image
reconstruction; 2) the optimization of scan acquisition parameters (current and
tube voltage reduction). Premedication (beta-blocker) was used for all children
to obtain heart rate < 80 BPM. Effective dose (ED) was calculated with the
dose-length product method with a conversion factor adjusted for patient age.
Image quality was evaluated by the referent physician. Scans were classified
as « excellent », « good » or « with significant artifacts ». 
Results: Patients were divided in three age groups: 0-4, 5-7 and 8-18
years. After adjustment for scan settings, median ED decreased by 28% (3.9
mSv, IQR 2.8-4.2), 40% (0.9 mSv, IQR 0.6-2.6) and 65% (0.7 mSv, IQR 0.5-
0.9) for 0-4, 5-7 and 8-18 years age groups (p< 0.05), respectively. The pro-
spective protocol (PULSE) was used in 40% of children. The reduction in
radiation dose was not associated with reduction in diagnostic image quality. 
Conclusions: Coronary CT can be obtained at very low radiation doses in
pediatric patients using ASIR and prospective ECG-triggered acquisition with
optimized scan parameters.
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Objectives: This study was design to assess the influence of extracardiac
or chromosomal anomalies on parental decision of termination of pregnancy
and on survival rates in newborns with prenatally diagnosed congenital heart
diseases.
Methods and results: 2057 consecutive foetuses with congenital heart
disease diagnosed from January 2002 to December 2011 were included: 1258
(61%) in-born neonates and 799 (39%) terminations of pregnancy (TOP). The
overall prevalence of major extracardiac or chromosomal anomalies was
18,6%. Of the 1258 newborns, 121 had a major associated anomaly but only
55 were identified before birth. Prenatally identified associated anomalies
were significantly lower in the newborn group in comparison with the TOP
group (4% vs 31%, p<0,0001). They were also lower in the surviving group
at one year of follow up (7,5% vs 20,7%, p<0,0001). A 4-fold increase of
death rate was observed if an associated anomaly was identified (IC95%[2,5-
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6,7], p<0,0001). These associations remained significant after multiple logistic
regression analysis including the severity of the heart defect (univentricular or
biventricular physiology).
Conclusion: Women are more likely to terminate pregnancy if extracar-
diac or chromosomal anomalies are associated. Post natal survival is strongly
influenced by these associated anomalies.
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This study was to review experience and outcomes of supraventricular
(SV) arrhythmias in fetus Methods: Cases were divided in groups: SVPB=
premature SV beats, NSSVT= non-sustained SV tachycardia, SSVT= sus-
tained SV tachycardia, and AF= atrial flutter. Heart failure (HF) was defined
as foetal hydrops or isolated effusion (pericardial or pleural or ascitis). Out-
come was favourable if arrhythmia resolved or stabilized until full-term birth,
not-favourable if premature birth or foetal death occurred. 
Results: 188 fetuses were included:89 in SVPB(47.3%), 31 in
NSSVT(16.5%), 60 in SSVT(31.9%), 8 in AF(4.3%), aged at diagnosis
30.8±4.5weeks (no difference between groups). Foetus HR at diagnosis was
241±30bpm in SSVT vs 226±26 in AF. Antiarrhytmic therapy was adminis-
tered in sustained tachycardia (83% of SSVT and 71% AF): 28 had 1 medica-
tion, 25: 2 medications, 2: 3 medications. Complication occurred in 29 cases,
all in SSVT and AF (29 of 68= 43%): 18 hydrops, 5 ascitis, 4 pericarditis,
1 pleural effusion and 1 LVdysfunction+MR, was more frequent in SSVT
(86%: hydrops in 30%) than AF (51%: no hydrops), p= 0.08. Fetal HF was
associated with HR at diagnosis: 251±25bpm in hydrops vs 228±31bpm in no-
hydrops (p=0.025). Outcome was favourable in SVPB and NSSVT, in 45 of
SSVT+AF (79%). Tachycardia resolved in 36, more frequently in SSVT
(57%) than AF (25%). HR only decreased in 9cases. Premature birth occurred
in 10, foetal death in 2. Outcome was not associated with HR or weeks of ges-
tation at diagnosis. Defavourable outcome was more frequent in hydrops or
isolated effusion (57%) than in uncomplicated cases (10%, p= 0.0002). Reso-
lution occurred in 45% hydrops vs 66% of non-hydrops cases. Digoxine
decreased from 79% of cases before 2000 to 33% after 2000, while flecaine
increased from 14% to 48.5%. There was no relationship between therapy or
number of medications and outcomes. 
Conclusion: Fetal SSVT more frequently resolves but has worse outcome
than AF, especially if HR at diagnosis is high and hydrops occurs. Larger
scale prospective studies are needed to evaluate the efficacy of flecaine com-
pared to digoxine therapy. 
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Risk markers of cardio-vascular events in children with Marfan syndrome
remain little known. Aortic root z-score measurements have been recently
updated. We assessed the prognostic value of aortic root z-score in patients
with Marfan syndrome diagnosed during childhood.
Methods: From the French multicenter database, 457 patients with Marfan
syndrome, diagnosed before 18 y.o., without a history of cardiac event were
prospectively included in this cohort study. Echocardiographic measurements
of aortic root diameters were performed at each visit. We calculated the Z-
score of aortic root measurements using the Bichat formula for each visit.
Mean z-score was defined as the mean of the z-score (MeanZS15) calculated
for each measurement before the age of 16.
Results: Median age at end of FU was 15.9 years (interquartile 10.9-20.3).
FU was complete for 69.5% of patients. Median FU was 4.6 years. A cardio-
vascular event occurred in 17 patients (3.7%, prophylactic aortic surgery
n=14, aortic dissection n=1 and deaths n=2). Survival free of cardiac events
was 85.1% in patients with a meanZS15 of the Valsalva diameter <3 and
56.4% in patients with a meanZS15 of the Valsalva diameter ≥3 (p<0.0001 by
log-rank test).In univariate analysis, Valsalva meanZS15 ≥3, age at inclusion
in the database, a lower heart rate and an increased arm/height ratio were asso-
ciated with an increasing risk of cardiac events (p<0.0001, p=0.04, p=0.01 and
p=0.04 respectively). After multivariate adjustment using a cox proportional
hazards model, only Valsalva meanZS15 ≥3 and lack of FBN1 or TGBB
mutation identified were associated with an increasing risk of cardiac events
(p<0.0001 and p=0.04 respectively).
Conclusion: Valsalva meanZS15 may help to predict whose children with
a Marfan syndrome will have a cardio-vascular event. Therefore a particular
attention to beta-blockade treatment observance and a regular follow-up may
be suggested in high-risk children. 
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Objectives: Left ventricular ejection causes a forward flow in the fetal
aortic isthmus while right ventricle (RV) has a retrograde influence. The
objective of this study was to test the hypothesis that non restrictive ventric-
ular septal defects (VSD) could cancel out the normal fetal RV preponderance
and its retrograde systolic effect on the isthmic flow pattern.
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